Preliminary Final Report
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
26 August 2026
Appendix 4E Preliminary Final Report
For the year ended 30 June 2026. Previous corresponding period: year ended
30 June 2025. Given to ASX under Listing Rule 4.3A.
Biome delivers a record year of profitable growth
Sales revenue of $23.9m, up 30% on FY25 ($18.4m)
Gross profit of $14.9m, up 33%
Gross margin of 62.1%1
(FY25: 61.1%)
EBITDA excluding share-based payments of $2.0m, up 115% on FY25
($0.9m)
Net profit before tax of $1.2m, up 453% on FY25 ($0.2m)
Net profit after tax of $3.6m (FY25: $0.2m), including first-time
recognition of a non-cash deferred tax asset of $2.4m
Net assets of $9.4m (FY25: $4.7m), with borrowings reduced to $1.9m
EPS increased to 1.62 cents, up from FY25 (0.10 cents)
Net operating cash inflow of $1.6m, a $4.5m turnaround on the FY25
outflow of $2.9m.
Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or
‘the company’) is pleased to release its Appendix 4E preliminary final report for
the year ended 30 June 2026, reporting audited net profit after tax of
$3,608,226 (FY25: $214,656). The result was underpinned by continued strength
in the Activated Probiotics®
range, supported by the Activated Therapeutics®
range launched in June 2025.
1
Gross margin calculated on sales to customers in the ordinary course of business only.
Key Financial Highlights
Sales revenue rose 30% to $23,883,240 (FY25: $18,417,188). Gross profit grew
33% to $14,936,188, with gross margin of 62.1% (FY25: 61.1%). Total operating
expenses rose 25.7% to $14,001,150, below revenue growth and demonstrating
operating leverage. EBITDA excluding share-based payments rose 115% to
$2,000,296 (FY25: $931,048). Statutory EBITDA was $1,653,787 (FY25: $524,522).
Net profit before tax was $1,186,919, 5.5 times the FY25 result of $214,656.
The after-tax result also reflects the first-time recognition of a deferred tax
asset of $2,421,307. This is a non-cash item. It reflects the board’s assessment
that it is probable future taxable profits will be available to use carried-forward
tax losses. Basic earnings per share was 1.62 cents (FY25: 0.10 cents) and
diluted earnings per share was 1.59 cents.
Biome strengthened its balance sheet during the year. Cash was $3,551,175 at
30 June 2026, with a further $3,100,000 available under total NAB facilities of
$5,000,000. Net operating cash inflow was $1,626,949, a turnaround of
$4,517,753 on the FY25 outflow of $2,890,804. Borrowings reduced by
$1,005,413 to $1,900,000. Net assets increased to $9,379,697 (FY25: $4,675,367)
and net tangible assets were 3.92 cents per share (FY25: 2.06 cents).
No dividend was paid, recommended or declared during FY26.
EBITDA excluding share-based payments and total operating expenses are
non-IFRS measures. They are unaudited and are derived from the audited
financial statements for the year ended 30 June 2026.
Blair Vega Norfolk, Founder and Managing Director, commented:
“FY26 was the year the model proved itself. Biome Daily became the number
one probiotic in Australian pharmacy by both units and value, we signed a
binding onshore manufacturing agreement with Specialty Probiotics
Australia at no capital cost to Biome, and we secured new distribution
through Fullscript in Canada and Uniphar in Ireland. The BMB18 clinical
program progressed at La Trobe University and at the University of Athens. I
want to thank our sales, marketing, education and finance teams for the
discipline behind this result. The platform we built in FY26 sets Biome up for a
step change in FY27.”
Lauren Dwyer, Chief Financial Officer, commented:
“FY26 was an inflection point. Revenue grew 30%, gross profit grew 33%, and
EBITDA excluding share-based payments rose 115%. Net profit after tax was
$3,608,226, which includes the first-time recognition of a deferred tax asset of
$2,421,307. Just as importantly, we generated $1,626,949 in operating cash
and reduced borrowings by $1,005,413. Biome ended the year with a
materially stronger balance sheet.”
-ENDS-
This announcement has been authorised for release by the Board of Biome
Australia Limited.
Investor Hub
Biome has launched a new interactive investor hub. To view a video
presentation of this announcement, ask questions or sign up for future
company updates, visit https://investorhub.biomeaustralia.com
About Biome Australia Limited
Biome Australia develops, licenses, commercialises and markets innovative,
evidence-based live biotherapeutics (probiotics) and complementary
medicines, many of which are supported by clinical research. Biome aims to
improve health outcomes and quality of life, and make its products accessible
to all.
Incorporated in Australia in 2018, Biome distributes locally and abroad. In
partnership with some of the world’s leading organisations in microbiome
research and development, Biome produces unique live biotherapeutic
(probiotic) products with innovative delivery technologies that improve their
stability and efficacy to create its flagship range of complementary medicines:
Activated Probiotics®
.
Supported by clinical research, including randomised double-blind placebo-
controlled trials, Activated Probiotics and Activated Therapeutics help prevent
and support the management of various health concerns, including low mood
and sleep, bone health, iron malabsorption, mild eczema and IBS. Through
practitioner and pharmacy channels, Biome is committed to educating health
professionals on the systemic health effects of the gut microbiota, helping
them to provide innovative, evidence-based natural medicines for the
management of some of humanity’s most prevalent and chronic health
concerns.
For more information visit: www.biomeaustralia.com
Investor Relations
Lauren Dwyer
corporate@biomeaustralia.com
(03) 9017 5800
Media enquiries
media@activated.co
Forward Looking Statements
This release contains forward looking statements, including projections,
guidance on future revenues, earnings and estimates regarding Biome’s
future performance (Forward Looking Statements). Forward Looking
Statements are provided as general guidance only and should not be relied
upon as an indication or guarantee of future performance. Actual results,
performance or achievements may differ materially from those expressed or
implied in Forward Looking Statements. Such statements assume the success
of Biome’s business strategies. You are cautioned not to place undue reliance
on Forward Looking Statements.
Forward Looking Statements are based on information available to Biome as
at the date of this release. Nothing in this release is a promise or
representation as to the future. No representation or warranty, express or
implied, is made as to the accuracy, likelihood of achievement or
reasonableness of Forward Looking Statements contained in this release.
Except as required by law or regulation (including the ASX Listing Rules),
Biome does not undertake to provide additional or updated information
whether as a result of changed expectations, new information, future events
or otherwise.
To the maximum extent permitted by law, Biome excludes and expressly
disclaims all liabilities in respect of, and makes no representation or warranty,
express or implied as to the fairness, currency, accuracy, reliability or
completeness of information in this release or the accuracy, likelihood of
achievement or reasonableness of Forward Looking Statements contained in,
implied by, or part of this release, or that this release contains all material
information about Biome which prospective investors may require in
evaluating a possible investment in Biome.
Biome Australia Limited
Appendix 4E
Preliminary final report
1. Company details
Name of entity: Biome Australia Limited
ABN: 51 627 364 014
Reporting period: For the year ended 30 June 2026
Previous period: For the year ended 30 June 2025
2. Results for announcement to the market
$
Revenues from ordinary activities up 29.7% to 23,883,240
Profit from ordinary activities after tax attributable to the owners of Biome
Australia Limited up 1580.9% to 3,608,226
Profit for the year attributable to the owners of Biome Australia Limited up 1580.9% to 3,608,226
Dividends
There were no dividends paid, recommended or declared during the current financial period.
Comments
The profit for the consolidated entity after providing for income tax amounted to $3,608,226 (30 June 2025: $214,656).
Biome Australia Limited
Appendix 4E
Preliminary final report
Review of operations
FY26 was the strongest year in Biome's history. Biome Daily, the Company's flagship product, is now the number one probiotic
product in Australian pharmacy by both units and dollar value (IQVIA(1)). June 2026 was a landmark month, with consumer
sell-through of the Activated Probiotics® range surpassing 100,000 units for the first time.
In Q4 FY26, Biome signed a binding manufacturing agreement with Specialty Probiotics Australia (SPA) for onshore
production of the Activated Probiotics range, at zero capital investment to Biome, with the first commercial batch targeted for
September 2026. The agreement is expected to structurally improve cost of goods sold and free up working capital through
shorter inventory and freight lead times.
Biome's international revenue from customers increased 20% to $1,784,093 across four markets (FY25: $1,486,689). In
Canada, a distribution partnership with Fullscript was secured in 2H FY26. In Ireland, a distribution agreement secured with
Uniphar is developing the European market, giving Biome a distribution partner in a second international territory.
A clinical trial for BMB18 - Biome's first wholly proprietary probiotic strain – is underway across the University of Athens,
alongside La Trobe University in Melbourne. This is expected to build long-term IP value as Biome extends its practitioner-
grade brand and distribution footprint into new export markets.
Financial Performance
The Company continued to experience strong sales growth during the year with revenue increasing by 30% to $23,883,240
compared to the previous corresponding period (FY25: $18,417,188). Gross profit on sales grew by 33% to $14,936,188
(FY25: $11,256,288), with a corresponding gross margin attributable on sales to customers of 62.1% (FY25: 61.1%). The
improvement in gross profit margin reflects a combination of sales pricing-mix improvements, as well as early gains from the
Company’s wider operational and inventory optimisation plan and continued progress toward its 65%+ gross margin target.
The strong sales growth has been driven by Biome's Activated Probiotics® range, further strengthened by the launch of the
Activated Therapeutics® range in June 2025, broadening Biome's practitioner-grade portfolio and creating an additional
platform for growth into FY27.
Total underlying operating expenses for the year increased by $2,859,133 to $14,001,150, well below the Company's 30%
revenue growth and demonstrating growing operating leverage in the underlying business. The Company continued to
deliberately reinvest in expanding international markets and distribution points during FY26, positioning the business ahead
of the growth and development planned for FY27 and beyond.
Earnings before interest, tax, depreciation and amortisation (EBITDA) excluding share-based payments in FY26 was
$2,000,296, 115% up on FY25 ($931,048).
The combination of stronger sales, higher gross margin and contained operating costs helped deliver a 5.5 times multiple
improvement in Net Profit Before Tax of $1,186,919 (FY25: $214,656). This result was significantly strengthened by the
recognition of a Deferred Tax Asset of $2,421,307, reflecting the Board's increased confidence in the Company's ability to
utilise its carried-forward tax losses against future taxable profits. This uplift materially improved basic earnings per share to
1.62 cents for FY26 (FY25: 0.10 cents), providing a stronger underlying earnings base as the Company scales into FY27.
The profit for the consolidated entity after providing for income tax amounted to $3,608,226 (30 June 2025: $214,656).
Financial Position
The Company has $3,551,175 in cash as at 30 June 2026 and a further $3,100,000 in an undrawn credit facility. Biome
delivered a full-year net operating cash inflow of $1,626,949, a turnaround of $4,517,753 on the FY25 net operating cash
outflow of $2,890,804. The Company continued to strengthen its balance sheet through disciplined capital management,
reducing debt by $1,005,413 year-on-year to just $1,900,000 drawn against total NAB facilities of $5,000,000.
The net assets of the Company increased to $9,379,697 as at 30 June 2026 (30 June 2025: $4,675,367), a result of increased
capital from the Company reporting a net profit for the year, the recognition of a Deferred Tax Asset and the exercise of
company options.
1 IQVIA™ Sell Out Service, VITAMINS MINERALS AND SUPPLEMENTS category, CHC3=PROBIOTICS, Australia Pharmacy, Total Value and Unit, 52
Weeks W/E 2026-06-27.
Biome Australia Limited
Appendix 4E
Preliminary final report
3. Net tangible assets
Reporting
period
Previous
period
Cents Cents
Net tangible assets per ordinary security 3.92 2.06
4. Control gained over entities
Not applicable.
5. Loss of control over entities
Not applicable.
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current financial period.
Previous period
There were no dividends paid, recommended or declared during the previous financial period.
7. Dividend reinvestment plans
Not applicable.
8. Details of associates and joint venture entities
Not applicable.
9. Foreign entities
Details of origin of accounting standards used in compiling the report:
Not applicable.
10. Audit qualification or review
Details of audit/review dispute or qualification (if any):
The financial statements have been audited and an unmodified opinion has been issued.
11. Attachments
Details of attachments (if any):
The Preliminary Final Report of Biome Australia Limited for the year ended 30 June 2026 is attached.
Biome Australia Limited
Statement of profit or loss and other comprehensive income
For the year ended 30 June 2026
Consolidated
Note 30 June 2026 30 June 2025
$ $
The above statement of profit or loss and other comprehensive income should be read in conjunction with the
accompanying notes
4
Revenue
Revenue from customers 5 23,883,240 18,417,188
Changes in inventories of finished goods and freight inwards (8,947,052) (7,160,900)
Other income 6 718,749 410,251
Expenses
Employee costs 7 (7,843,093) (6,353,347)
Warehouse, wholesale and distribution costs (1,215,333) (1,141,337)
Advertising and promotional expenses (1,792,725) (1,164,053)
Travel and entertainment expenses (827,563) (781,023)
Freight and logistics expenses (598,716) (368,438)
Professional and consulting fees (508,506) (447,695)
Other expenses (1,215,214) (886,124)
Earnings before interest, tax, depreciation and amortisation (EBITDA) 1,653,787 524,522
Depreciation and amortisation 7 (352,272) (241,970)
Net interest expense (114,596) (67,896)
Profit before income tax benefit 1,186,919 214,656
Income tax benefit 8 2,421,307 -
Profit after income tax benefit for the year attributable to the owners of Biome
Australia Limited 25 3,608,226 214,656
Other comprehensive income for the year, net of tax 9,724 -
Total comprehensive income for the year attributable to the owners of Biome
Australia Limited 3,617,950 214,656
Cents Cents
Basic earnings per share 35 1.62 0.10
Diluted earnings per share 35 1.59 0.10
Biome Australia Limited
Statement of financial position
As at 30 June 2026
Consolidated
Note 30 June 2026 30 June 2025
$ $
The above statement of financial position should be read in conjunction with the accompanying notes
5
Assets
Current assets
Cash and cash equivalents 9 3,551,175 2,746,416
Trade and other receivables 10 3,733,115 4,327,593
Inventories 11 3,976,425 4,111,914
Other 12 303,864 255,306
Total current assets 11,564,579 11,441,229
Non-current assets
Property, plant and equipment 13 276,576 224,585
Right-of-use assets 14 1,005,886 138,887
Intangibles 15 447,569 163,239
Deferred tax assets 16 2,421,307 -
Total non-current assets 4,151,338 526,711
Total assets 15,715,917 11,967,940
Liabilities
Current liabilities
Trade and other payables 17 2,461,075 3,600,102
Borrowings 18 1,900,000 2,905,413
Lease liabilities 19 260,680 116,833
Employee benefits 20 831,063 557,676
Total current liabilities 5,452,818 7,180,024
Non-current liabilities
Lease liabilities 21 807,296 50,979
Employee benefits 22 76,106 61,570
Total non-current liabilities 883,402 112,549
Total liabilities 6,336,220 7,292,573
Net assets 9,379,697 4,675,367
Equity
Issued capital 23 24,194,199 23,323,346
Reserves 24 494,020 406,618
Accumulated losses 25 (15,308,522) (19,054,597)
Total equity 9,379,697 4,675,367
Biome Australia Limited
Statement of changes in equity
For the year ended 30 June 2026
The above statement of changes in equity should be read in conjunction with the accompanying notes
6
Issued Option Accumulated
Total equity
capital Reserves losses
Consolidated $ $ $ $
Balance at 1 July 2024 21,727,165 444,212 (19,267,849) 2,903,528
Profit after income tax expense for the year - - 214,656 214,656
Other comprehensive income for the year, net of tax - - - -
Total comprehensive income for the year - - 214,656 214,656
Transactions with owners in their capacity as owners:
Share-based payments (note 36) 471,619 (37,594) - 434,025
Exercise of options 1,124,562 - - 1,124,562
Consolidation - currency adjustment - - (1,404) (1,404)
Balance at 30 June 2025 23,323,346 406,618 (19,054,597) 4,675,367
Issued Option Accumulated
Total equity
capital Reserves losses
Consolidated $ $ $ $
Balance at 1 July 2025 23,323,346 406,618 (19,054,597) 4,675,367
Profit after income tax benefit for the year - - 3,608,226 3,608,226
Other comprehensive income for the year, net of tax - - 9,724 9,724
Total comprehensive income for the year - - 3,617,950 3,617,950
Transactions with owners in their capacity as owners:
Share-based payments (note 36) 345,853 215,527 - 561,380
Expiry of options - (128,125) 128,125 -
Exercise of options 525,000 - - 525,000
Balance at 30 June 2026 24,194,199 494,020 (15,308,522) 9,379,697
Biome Australia Limited
Statement of cash flows
For the year ended 30 June 2026
Consolidated
Note 30 June 2026 30 June 2025
$ $
The above statement of cash flows should be read in conjunction with the accompanying notes
7
Cash flows from operating activities
Receipts from customers (inclusive of GST) 24,178,197 16,833,117
Payments to suppliers (inclusive of GST) (23,007,344) (19,994,220)
R&D tax refund and government grants 656,644 410,251
Interest paid on lease liabilities (181,289) (139,952)
Income taxes and FBT paid (19,259) -
Net cash from/(used in) operating activities 4 1,626,949 (2,890,804)
Cash flows from investing activities
Payments for property, plant and equipment 13 (204,376) (37,138)
Payments for intellectual property (284,330) (163,239)
Net cash used in investing activities (488,706) (200,377)
Cash flows from financing activities
Proceeds from exercise of options 23 525,000 1,124,562
Proceeds from repayment of Employee Loan Funded Share Plan - 27,500
Interest received - 71,145
Repayments for lease liabilities (206,916) (108,952)
Proceeds from issues of equity securities (excluding convertible debt securities) 353,845 -
Proceeds from borrowings - 2,904,816
Repayment of borrowings (1,005,413) (1,050,000)
Net cash from/(used in) financing activities (333,484) 2,969,071
Net increase/(decrease) in cash and cash equivalents 804,759 (122,110)
Cash and cash equivalents at the beginning of the financial year 2,746,416 2,868,526
Cash and cash equivalents at the end of the financial year 9 3,551,175 2,746,416
Biome Australia Limited
Notes to the financial statements
30 June 2026
8
Note 1. General information
The financial statements cover Biome Australia Limited as a consolidated entity consisting of Biome Australia Limited and the
entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is
Biome Australia Limited's functional and presentation currency.
Biome Australia Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered
office and principal place of business are:
Registered office Principal place of business
192-194 Johnston Street 192-194 Johnston Street
Collingwood Victoria 3066 Collingwood Victoria 3066
A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report,
which is not part of the financial statements.
The financial statements were authorised for issue, in accordance with a resolution of directors, on 25 August 2026. The
directors have the power to amend and reissue the financial statements.
Note 2. Material accounting policy information
The accounting policies that are material to the consolidated entity are set out either in the respective notes or below. The
accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.
New or amended Accounting Standards and Interpretations adopted
The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the
Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.
Basis of preparation
These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and
Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate
for for-profit oriented entities. These financial statements also comply with IFRS Accounting Standards as issued by the
International Accounting Standards Board ('IASB').
Historical cost convention
The financial statements have been prepared under the historical cost convention, except for, where applicable, the
revaluation of financial assets and liabilities at fair value through profit or loss, financial assets at fair value through other
comprehensive income, investment properties, certain classes of property, plant and equipment and derivative financial
instruments.
Critical accounting estimates
The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires
management to exercise its judgement in the process of applying the consolidated entity's accounting policies. The areas
involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial
statements, are disclosed in note 3.
Parent entity information
In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only.
Supplementary information about the parent entity is disclosed in note 32.
Biome Australia Limited
Notes to the financial statements
30 June 2026
Note 2. Material accounting policy information (continued)
9
Revenue recognition
The consolidated entity recognises revenue as follows:
Revenue from contracts with customers
Revenue is recognised at an amount that reflects the consideration to which the consolidated entity is expected to be entitled
in exchange for transferring goods or services to a customer. For each contract with a customer, the consolidated entity:
identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price
which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to
the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to
be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer
to the customer of the goods or services promised.
Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts,
rebates and refunds, any potential bonuses receivable from the customer and any other contingent events. Such estimates
are determined using either the 'expected value' or 'most likely amount' method. The measurement of variable consideration
is subject to a constraining principle whereby revenue will only be recognised to the extent that it is highly probable that a
significant reversal in the amount of cumulative revenue recognised will not occur. The measurement constraint continues
until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject
to the constraining principle are recognised as a refund liability.
Sale of goods
Revenue from the sale of goods is recognised at the point in time when the customer obtains control of the goods, which is
generally at the time of delivery.
Interest
Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the
amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate,
which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the
net carrying amount of the financial asset.
Other revenue
Other revenue is recognised when it is received or when the right to receive payment is established.
Income tax
The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable
income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary
differences, unused tax losses and the adjustment recognised for prior periods, where applicable.
Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when the
assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for:
● When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a
transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor
taxable profits; or
● When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the
timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable
future.
Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future
taxable amounts will be available to utilise those temporary differences and losses.
The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax
assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the
carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable
that there are future taxable profits available to recover the asset.
Biome Australia Limited
Notes to the financial statements
30 June 2026
Note 2. Material accounting policy information (continued)
10
Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against
current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on
either the same taxable entity or different taxable entities which intend to settle simultaneously.
Biome Australia Limited (the 'head entity') and its wholly-owned Australian subsidiaries have formed an income tax
consolidated group under the tax consolidation regime. The head entity and each subsidiary in the tax consolidated group
continue to account for their own current and deferred tax amounts. The tax consolidated group has applied the 'separate
taxpayer within group' approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated
group.
In addition to its own current and deferred tax amounts, the head entity also recognises the current tax liabilities (or assets)
and the deferred tax assets arising from unused tax losses and unused tax credits assumed from each subsidiary in the tax
consolidated group.
Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognised as amounts
receivable from or payable to other entities in the tax consolidated group. The tax funding arrangement ensures that the
intercompany charge equals the current tax liability or benefit of each tax consolidated group member, resulting in neither a
contribution by the head entity to the subsidiaries nor a distribution by the subsidiaries to the head entity.
Impairment of non-financial assets
Non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount
exceeds its recoverable amount.
Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the
present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or
cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to
form a cash-generating unit.
Reinstatement of comparatives
Certain comparative amounts have been reclassified to conform w
Share your feedback
Discover